Last reviewed 2026-04-23 · How we verify

HPP2201

HPP2201 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.

HPP2201 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.

At a glance

Mechanism of action

HPP2201 activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained metabolic benefits.

Approved indications

• Type 2 diabetes mellitus
• Obesity or weight management

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

Key clinical trials

• A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.